Dr.sophia Randolph

Biography

Dr. Randolph previously served as Franchise Clinical Lead for the IBRANCE® clinical program at Pfizer, Inc., leading the early and late clinical development of this asset with initial registrations in the U.S. and rest of world. Before joining Pfizer, Dr. Randolph served as ZOLINZA® Clinical Lead at Merck, Inc., responsible for design and implementation of its hematology clinical life cycle plan as well as Molecular Profiling Lead, creating clinical trial translational plans across several oncology early development programs. Dr. Randolph received her M.D. and Ph.D. in cellular and molecular biology from University of Michigan and completed her oncology fellowship training at Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center where she studied hematopoietic cell transplant engineering methods to improve the graft-versus-leukemia effect for transplant patients. Dr. Randolph received her A.B. in biochemistry from Harvard University. Dr. Randolph previously served as Franchise Clinical Lead for the IBRANCE® clinical program at Pfizer, Inc., leading the early and late clinical development of this asset with initial registrations in the U.S. and rest of world. Before joining Pfizer, Dr. Randolph served as ZOLINZA® Clinical Lead at Merck, Inc., responsible for design and implementation of its hematology clinical life cycle plan as well as Molecular Profiling Lead, creating clinical trial translational plans across several oncology early development programs. Dr. Randolph received her M.D. and Ph.D. in cellular and molecular biology from University of Michigan and completed her oncology fellowship training at Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center where she studied hematopoietic cell transplant engineering methods to improve the graft-versus-leukemia effect for transplant patients. Dr. Randolph received her A.B. in biochemistry from Harvard University.

Research Interest

cellular and molecular biology